Mr. János Bertók:

Lobbying is a very complex issue and the reality is very complex. This issue was discussed at the June lobbying forum and we saw there that lobbying techniques and forces are evolving. Many of the major sectors - the pharmaceutical sector was mentioned here - are major actors in this area and they are using certain techniques. They are financing think tanks or research laboratories. Of course, they are using non-profit organisations. More and more, even in Europe, grassroots lobbying is taking place. The method in the United States is very fundamental. From our perspective, this is a dynamic process. This means we must examine whether we would like to focus on the key signal that lobbyists exist and that other actors can also be used.

If this is happening and continues to happen, it can be grown, modified or extended based on experience and it could redefine the scope of the legislation and the reporting process.